Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Issues Quarterly Earnings Results

Key Points

• Bayer Aktiengesellschaft reported quarterly earnings of $0.35 EPS, exceeding analysts' expectations of $0.25 by $0.10.
• The company's revenue reached $12.42 billion, significantly higher than the consensus estimate of $10.79 billion.
• Despite the positive earnings report, analysts' ratings have varied, with some firms downgrading the stock while others have upgraded it to a strong-buy rating.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) issued its earnings results on Wednesday. The company reported $0.35 EPS for the quarter, topping the consensus estimate of $0.25 by $0.10, Zacks reports. The firm had revenue of $12.42 billion during the quarter, compared to the consensus estimate of $10.79 billion. Bayer Aktiengesellschaft had a positive return on equity of 15.48% and a negative net margin of 7.61%.

Bayer Aktiengesellschaft Stock Up 1.5%

BAYRY stock traded up $0.11 during midday trading on Tuesday, hitting $7.56. The stock had a trading volume of 162,073 shares, compared to its average volume of 813,481. The firm has a market cap of $29.71 billion, a price-to-earnings ratio of -7.79 and a beta of 0.91. The business has a 50-day moving average of $7.83 and a two-hundred day moving average of $6.76. Bayer Aktiengesellschaft has a 52-week low of $4.79 and a 52-week high of $8.65. The company has a debt-to-equity ratio of 1.07, a current ratio of 1.25 and a quick ratio of 0.79.

Analyst Upgrades and Downgrades

BAYRY has been the topic of a number of research analyst reports. Kepler Capital Markets upgraded Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a report on Wednesday, June 11th. Wall Street Zen raised Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a research report on Sunday. The Goldman Sachs Group upgraded Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research note on Thursday, June 5th. Finally, Hsbc Global Res raised Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a report on Wednesday, June 11th. One analyst has rated the stock with a hold rating, two have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Bayer Aktiengesellschaft presently has a consensus rating of "Buy".

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.